[ET Net News Agency, 6 June 2019] CStone Pharmaceuticals (02616) said it has received
approval to initiate clinical development in China of CS1001 in combination with BLU-554
in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). The trial
is a multi-centre, open-label, and multidose Phase Ib/II study that aims to evaluate the
safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumour efficacy of the
combination in advanced HCC.
CS1001 is a proprietary anti-PD-L1 monoclonal antibody developed by CStone, and one of
the company's three backbone immuno-oncology products. BLU-554 is a potent and highly
selective inhibitor of fibroblast growth factor receptor 4 discovered by CStone's partner,
Blueprint Medicines Corporation. (RC)